Although it is known that Trm with effector functions can be induced in the tumor (38), our data argue that the choice of adjuvant in cancer vaccination can lead to formation of progenitor exhausted CD8+ Trm T cells, and that formation of this population correlates with the capacity to control melanoma cells independently and in cooperation with anti-PD-1 immunotherapy. The gene discussed is CD8A; the disease is cancer.